INZY News and Press, Inozyme Pharma Inc. From 05/12/21

– Filed Clinical Trial Application for INZ-701 for ABCC6 Deficiency in Europe; on track to initiate Phase 1/2 clinical trial in mid-2021 – – Published peer-reviewed preclinical data supporting INZ-701 as a potential treatment for ENPP1 Deficiency in Journa...

Inozyme Pharma (INZY) presents preclinical data suggesting the utility of its lead candidate, INZ-701, as a potential treatment for ABCC6 Deficiency.The data, presented at the virtual European Calcified Tissue Society Annual Congress, held May 6-8, are the first to show that an enzyme replace...

BOSTON, May 07, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today presented preclinical data suggesting the utility of its lead clinical development can...

BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced that its co-founder, president, and CEO, Axel Bolte, MSc, MBA, will participate in a f...

- Peer-reviewed article in Journal of Bone and Mineral Research showed INZ-701 increased pyrophosphate (PPi) levels, improved disease markers, and decreased mortality in an ENPP1-deficient mouse model - - Preclinical findings support increase of PPi levels as a predictive...

BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today announced that preclinical data from a study examining INZ-701 for the pot...

Inozyme Pharma (INZY) presents data that highlight the burden of disease for patients and families affected by ENPP1 and ABCC6 Deficiency, two potentially deadly genetic diseases.A total of 38 respondents participated in the study. The most frequently reported burdens for patients with ENPP1 ...

BOSTON, April 14, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization disorders, today presented data that highlight the burden of disease for patients and families affected b...

BOSTON, April 08, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases of abnormal mineralization, today announced that data from the burden of illness in infantile onset...

BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. , a rare disease biopharmaceutical company developing novel therapeutics for the treatment of disorders of abnormal mineralization, announced today changes to its scientific advisory board (SAB), including the addition of t...